SCHEMBL4933057

SCHEMBL4933057

Cc1c(Br)cc(C(=O)OCc2ccccc2)cc1Br

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.62
KMT2A Q03164 3/20 0.62
SLC6A2 P23975 1/20 0.62
SLC6A3 Q01959 1/20 0.62
LMNA P02545 3/20 0.57
MAPT P10636 5/20 0.54
ALDH1A1 P00352 4/20 0.54
HPGD P15428 1/20 0.54
TSHR P16473 1/20 0.51
RAB9A P51151 7/20 0.51
NPC1 O15118 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GAA P10253 1/20 0.49
STAT1 P42224 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
POLB P06746 1/20 0.48
ATM Q13315 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282770 0.83 KMT2A (0.81) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL25713483 0.83 TDP1 (0.64) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL6287009 0.83 KMT2A (0.64) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL12020911 0.82 TDP1 (0.68) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL3919885 0.82 KMT2A (0.58) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL12563203 0.80 LMNA (0.64) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL3042119 0.79 TDP1 (0.64) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL5663353 0.79 TDP1 (0.64) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL26695099 0.79 KMT2A (0.63) TDP1KMT2ASLC6A2SLC6A3LMNA
Benzyl Benzoate SCHEMBL19206950 0.79 KMT2A (0.79) TDP1KMT2ASLC6A2SLC6A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 TDP1 2249/4885KMT2A 3849/4885SLC6A2 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.